A comprehensive study of the safety of using anti-Hepatitis B core (Hbc) positive subjects in living donor liver transplants

Hepato-Gastroenterology

Volumn 60, Issue 126, 2013, Pages 1426-1432

  Lei, Jianyong ^a   Yan, Lunan ^a   Wang, Wentao ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Cirrhosis; Hepatitis; Liver; Surgery; Transplant

Indexed keywords

ALANINE AMINOTRANSFERASE; AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; HEPATITIS B CORE ANTIBODY; PROTHROMBIN;

ABDOMINAL BLEEDING; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; BLOOD ANALYSIS; BLOOD AUTOTRANSFUSION; CONTROLLED STUDY; DEATH; DEMOGRAPHY; FEMALE; FOLLOW UP; HEPATIC ENCEPHALOPATHY; HOSPITALIZATION; HUMAN; HUMAN TISSUE; INTENSIVE CARE UNIT; INTERNATIONAL NORMALIZED RATIO; LABORATORY TEST; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FUNCTION; LIVER GRAFT; LIVER REGENERATION; LIVER TRANSPLANTATION; LIVING DONOR; LIVING DONOR LIVER TRANSPLANT; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; MULTIDETECTOR COMPUTED TOMOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; ORGAN DONOR; PATIENT SAFETY; PHYSICAL ACTIVITY; PLEURA EFFUSION; PORTAL VEIN THROMBOSIS; POSTOPERATIVE CARE; POSTOPERATIVE HEMORRHAGE; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROTHROMBIN TIME; QUALITY OF LIFE; REOPERATION; SEROLOGY; SHORT FORM 36; SOCIAL INTERACTION; STEATOSIS; THROMBOCYTE COUNT; WOUND INFECTION;

ADULT; ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; FEMALE; HEPATITIS B ANTIBODIES; HEPATITIS B CORE ANTIGENS; HUMANS; LIVER; LIVER TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; PLATELET COUNT;

EID: 84885748026     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: 10.5754/hge13062     Document Type: Article

References (36)

1. Heimbach JK, Wiesner RH: Benefit of living donor liver transplantation: Who and when? Hepatology 2011; 54:1125-1126.
2. Wachs ME, Amend WJ, Ascher NL, et al.: The risk of transmission of hepatitis B from HBsAg(-), HbcAb(+), HBIgM(-) organ donors. Transplantation 1995; 59:230-234.
3. Douglas D, Rakela J, Wright T, Krom RA, Wiesner RH: The clinical course of transplantation-associated de novo hepatitis B infection in the liver transplantation recipient. Liver Transpl Surg 1997; 3:105-111. (Pubitemid 27114021)
4. Dodson SF, Issa S, Araya V, Gayowski T, Eqhtesad B, Iwatsuki S, Montalvo E, Rakela J, Fung JJ: Infectivity of hepatic allografts with antibodies to hepatitis B virus. Transplantation 1997; 64:1582-1584. (Pubitemid 28047387)
5. Yu AS, Vierling JM, Colquhoun SD, Arnaout WS, Chan CK, Khanafshar E, Geller SA, Nichols WS, Fong TL: Transmission of hepatitis B infection from hepatitis B core antibody-positive liver allografts is prevented by lamivudine therapy. Liver Transpl 2001; 7:513-517. (Pubitemid 32547266)
6. Hwang S, Moon DB, Lee SG, et al.: Safety of anti-hepatitis B core antibody-positive donors for living-donor liver transplantation. Transplantation 2003; 75(3):S45-S48. (Pubitemid 36222989)
7. Lee KH, Wai CT, Lim SG, Manjit K, Lee HL, Da Costa M, Quak SH, Tan KC: Risk for de novo hepatitis B from antibody to hepatitis B core antigen-positive donors in liver transplantation in Singapore. Liver Transpl 2001; 7:469.
8. Lo C, Fan S, Liu C, Yong BH, Wong Y, Ng IO, Wong J: Safety and outcome of hepatitis B core antibody-positive donors in right-lobe living donor liver transplantation 2003; 9:827-832.
9. Chen YS, Wang CC, deVilla VH, Wang SH, Cheng YF, Huang TL, Jawan B, Chiu KW, Chen CL: Prevention of de nobo hepatitis B virus infection in living donor liver transplantation using hepatitis B core antibody positive donors. Clin Transpl 2002; 16:405-409. (Pubitemid 36004270)
10. Van thiel DH, De Maria N, Colantoni A, Friedlander L: Can hepatitis B core antibody positive livers be used safety for transplantation: hepatitis B virus detection in the liver of individual who are hepatitis B core antibody positive. Transplantation 1999; 68:519.
11. Burton J, Shaw-Stiffel T: Use of hepatitis B core antibody positive donors in recipients without evidence of hepatitis B infection: a survey of current practice in the United States. Liver Transpl 2003; 9:837-842. (Pubitemid 36974951)
12. Cholongitas E, Papatheodoridis GV, Burroughs AK: Liver graft from anti-hepatitis B core positive donors: a systematic review. J Hepatol 2010; 52(2):272-279.
13. Perrillo R: Hepatitis B virus prevention strategies for antibody to hepatitis B core antigen-positive liver donation: a survey of North American, European, and Asian-pacific transplantation programs. Liver Transpl 2009; 15:223-232.
14. Barcena R, Moraleda G, Moreno J, Martin MD, de Vucente E, Nuno J, Mateos ML, del Campo S: Prevention of de novo HBV infection by the presence of anti-HBs in transplanted patients receiving core antibody-positive livers. World J Gastroenterol 2006; 12:2070-2074.
15. Lin CC, Chen CL, Concejero A, et al.: Active immunization to prevent de novo hepatitis B virus infection in pediatric live donor liver recipients. A J Transplant 2007; 7:195-200.
16. Umeda M, Marusawa H, Ueda M, Takada Y, Egawa H, Uemoto S, Chiba T: Beneficial effects of short-term lamivudine treatment for de novo hepatitis B virus reactivation after liver transplantation. Am J Transplant 2006; 6:2680-2685. (Pubitemid 44571688)
17. Gish RG, Mccashland T: Hepatitis B in liver transplantation recipients. Liver Transpl 2006; 12:S54-S64.
18. Goddard CJ, Warnes TW: Raised liver enzymes in asymptomatic patients: investigation and outcome. Dig Dis 1992; 10:218.
19. Shi ZR, Yan LN, Li B, Wen TF: Evaluation of standard liver volume formulae for Chinese adults. World J Gastroenterol 2009; 15(32):4062-4066.
20. Taketomi A, Kayashima H, Soejima Y, et al.: Donor risk in adult-to-adult living donor liver transplantation: impact of left lobe graft Transplantation 2009; 87:445-450.
21. Sung J: Hepatitis B virus infection and its sequelae in Taiwan. Gastroenterol Jpn 1984; 19:363-366.
22. Jiang L, Yan LN: Current therapeutic strategies for recurrent hepatitis B virus infection after liver transplantation. World J Gastroenterol 2010; 16(20):2468-2475.
23. Jiang L, Yan L, Li B, Wen T, Zhao J, Jiang L, Cheng N, Wei Y, Yang J, Xu M, Wang W: Prophylaxis against hepatitis B recurrence posttransplantation using lamivudine and individualized low-dose hepatitis B immunoglobulin. Am J Transplant 2010; 10(8):1861-1869.
24. Vij V, Ramaswamy VK, Goia S, Dargan P, Mallya A, Goyal N, Gupta S: Intraoperative no go donor hepatectomy in living donor liver transplantation. Am J Transplant 2010; 10(9):2181-2182.
25. Cuba M, Adcock L, Macleod C, Cattral M, Greig P, Levy G, Grant D, Khalili K, McGilvray ID: Intraoperative 'no go' donor hepatectomies in living donor liver transplantation. Am J Transplant 2010; 10(3):612-618.
26. Goddard CJ, Warnes TW: Raised liver enzymes in asymptomatic patients: investigation and outcome. Dig Dis 1992; 10(4):218-226.
27. Rinella ME, Alonso E, Rao S, Whitington P, Fryer J, Abecassis M, Superina R, Flamm SL, Blei AT: Body mass index as a predictor of hepatic steatosis in living liver donors. Liver Transpl 2001; 7(5):409-414. (Pubitemid 32492578)
28. Trotter JF, Gillespie BW, Terrault NA, et al.: Laboratory test result after living liver donation in the adult-to-adult living donor liver transplantation cohort study. Liver Transpl 2011; 17:409-417.
29. Li C, Mi K, Wen TF, Yan LN, Li B: Outcome comparison of right hepatectomy for living liver donation versus for hepatic patients without cirrhosis. J Gastrointest Surg 2011; 15:982-987.
30. Vetelainen R, Bennink R], Viet AK, van Gulik TM: Mild steatosis impairs functional recovery after liver resection in an experimental model. Br J Surg 2007; 94(8):1002-1008. (Pubitemid 47236546)
31. Department of Health: Public Heath Report No.3 viral Hepatitis and Liver Cancer and Unintentional Injuries in Children. Hong Kong: Department of Health, 1998.
32. Liu CJ, Chen DS, Chen PJ: Epidemiology of HBV infection in Asian blood donors: emphasis on occult HBV infection and the role of NAT. J Clin Virol 2006; 36 Suppl 1:S33-44.
33. Yuen Lee CK, Wong DK, Fung J, et al.: Prevalence of occult hepatitis B infection in a highly endemic area for chronic hepatitis B: a study of a large blood donor population. Gut 2010; 59(10):1389-1393.
34. Alter MJ: Epidemiology of hepatitis B in Europe and worldwide. J Hepatol 2003; 39 Suppl 1:S64-69.
35. Alter MJ: Epidemiology and prevention of hepatitis B. Semin Liver Dis 2003; 23(1):39-46.
36. Okada S, Sato T, Okusaka T, Ishii H, Ikeda M, Nakasuka H, Kosakamoto H, Yoshimori M, Wakabayashi K: Past exposure to hepatitis B virus as a risk factor for hepatocelluar carcinoma in patients with chronic liver disease. Br J Cancer 1998; 77:2028-2031. (Pubitemid 28254652)